Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment
Oxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation. The aim of the study was the evaluation of the non-inferiority of three over six months treatment with FOLFOX o...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/14/3552 |
| _version_ | 1797527461261475840 |
|---|---|
| author | Asimina Koulouridi Ippokratis Messaritakis Emmanouil Theodorakis Maria Chondrozoumaki Maria Sfakianaki Nikolaos Gouvas John Tsiaoussis Dimitrios Mavroudis Maria Tzardi John Souglakos |
| author_facet | Asimina Koulouridi Ippokratis Messaritakis Emmanouil Theodorakis Maria Chondrozoumaki Maria Sfakianaki Nikolaos Gouvas John Tsiaoussis Dimitrios Mavroudis Maria Tzardi John Souglakos |
| author_sort | Asimina Koulouridi |
| collection | DOAJ |
| description | Oxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation. The aim of the study was the evaluation of the non-inferiority of three over six months treatment with FOLFOX or CAPOX, in stage III CRC patients. Peripheral blood samples from 121 patients were collected, at three time points during treatment and evaluated for circulating tumor cells (CTCs) and microbial DNA detection (16S rRNA, <i>Escherichia coli</i>, <i>Bacteroides fragilis</i>, <i>Candida albicans</i>). Of all patients, 41.3% and 58.7% were treated with FOLFOX and CAPOX, respectively. CTCs were significantly decreased and increased after three and six months of treatment, respectively. CAPOX tends to reduce the CTCs after 3 months, whereas there is a statistically significant increase of CTCs in patients under FOLFOX after 6 months. A significant correlation was demonstrated between microbial DNA detection and both CTCs detection at baseline and CTCs increase between baseline and three months of treatment. To conclude, the current study provides additional evidence of non-inferiority of three over 6 months of treatment, mainly in patients under CAPOX. |
| first_indexed | 2024-03-10T09:44:02Z |
| format | Article |
| id | doaj.art-67c00e4755294c4abeb20b0de887fada |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T09:44:02Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-67c00e4755294c4abeb20b0de887fada2023-11-22T03:25:13ZengMDPI AGCancers2072-66942021-07-011314355210.3390/cancers13143552Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant TreatmentAsimina Koulouridi0Ippokratis Messaritakis1Emmanouil Theodorakis2Maria Chondrozoumaki3Maria Sfakianaki4Nikolaos Gouvas5John Tsiaoussis6Dimitrios Mavroudis7Maria Tzardi8John Souglakos9Laboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, GreeceLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, GreeceLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, GreeceLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, GreeceLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, GreeceMedical School, University of Cyprus, 20537 Nicosia, CyprusDepartment of Anatomy, School of Medicine, University of Crete, 70013 Heraklion, GreeceLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, GreeceLaboratory of Pathology, Medical School, University of Crete, 70013 Heraklion, GreeceLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, GreeceOxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation. The aim of the study was the evaluation of the non-inferiority of three over six months treatment with FOLFOX or CAPOX, in stage III CRC patients. Peripheral blood samples from 121 patients were collected, at three time points during treatment and evaluated for circulating tumor cells (CTCs) and microbial DNA detection (16S rRNA, <i>Escherichia coli</i>, <i>Bacteroides fragilis</i>, <i>Candida albicans</i>). Of all patients, 41.3% and 58.7% were treated with FOLFOX and CAPOX, respectively. CTCs were significantly decreased and increased after three and six months of treatment, respectively. CAPOX tends to reduce the CTCs after 3 months, whereas there is a statistically significant increase of CTCs in patients under FOLFOX after 6 months. A significant correlation was demonstrated between microbial DNA detection and both CTCs detection at baseline and CTCs increase between baseline and three months of treatment. To conclude, the current study provides additional evidence of non-inferiority of three over 6 months of treatment, mainly in patients under CAPOX.https://www.mdpi.com/2072-6694/13/14/3552colorectal cancerstage IIIadjuvant chemotherapycirculating tumor cellsmicrobial DNAthree vs. six months adjuvant treatment |
| spellingShingle | Asimina Koulouridi Ippokratis Messaritakis Emmanouil Theodorakis Maria Chondrozoumaki Maria Sfakianaki Nikolaos Gouvas John Tsiaoussis Dimitrios Mavroudis Maria Tzardi John Souglakos Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment Cancers colorectal cancer stage III adjuvant chemotherapy circulating tumor cells microbial DNA three vs. six months adjuvant treatment |
| title | Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment |
| title_full | Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment |
| title_fullStr | Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment |
| title_full_unstemmed | Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment |
| title_short | Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment |
| title_sort | detection of circulating tumor cells and microbial dna fragments in stage iii colorectal cancer patients under three versus six months of adjuvant treatment |
| topic | colorectal cancer stage III adjuvant chemotherapy circulating tumor cells microbial DNA three vs. six months adjuvant treatment |
| url | https://www.mdpi.com/2072-6694/13/14/3552 |
| work_keys_str_mv | AT asiminakoulouridi detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT ippokratismessaritakis detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT emmanouiltheodorakis detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT mariachondrozoumaki detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT mariasfakianaki detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT nikolaosgouvas detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT johntsiaoussis detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT dimitriosmavroudis detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT mariatzardi detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment AT johnsouglakos detectionofcirculatingtumorcellsandmicrobialdnafragmentsinstageiiicolorectalcancerpatientsunderthreeversussixmonthsofadjuvanttreatment |